Recross packaging beside the pre-filled syringe

Recross

Sodium hyaluronate intra-articular solution for viscosupplementation in osteoarthritis and sports medicine. Play Sure Doping Free certified. CE marked.

Not to scale. Product shown enlarged for detail.

Recross packaging
Recross pre-filled syringe
Indication & Usage

Osteoarthritis: viscosupplementation

Recross is indicated for the relief of pain in osteoarthritis of the knee, hip, and shoulder in patients who have failed to respond adequately to conservative non-pharmacological therapy and simple analgesics. Administered by intra-articular injection by a qualified physician.

01
Injection regimen

A single 4.0 mL injection. The effect lasts at least six months after the first injection.

02
Administration

Intra-articular injection by a qualified physician. Do not inject intravenously. Strict aseptic technique required.

03
Play Sure Doping Free certification

Recross is Play Sure Doping Free certified and contains no prohibited substances. Safe for use in competitive athletes subject to WADA testing. Confirm current WADA list at time of use.

Product Specifications

Technical specifications

Formulation data, regulatory classification, injection parameters, and handling requirements for Recross sodium hyaluronate.

HA Type
Sodium Hyaluronate: moderately cross-linked + linear (HXL)
Concentration
22 mg/mL (88 mg / 2.2%)
Volume per Syringe
4.0 mL
Injection Regimen
Single shot · effect lasts at least 6 months
Presentation
Pre-filled syringe, ready to use
Expiry
Do not use after the date printed on the pack
Storage
2°C to 25°C, protect from light and shocks, do not freeze
Regulatory
CE Class III (MDD 93/42/EEC) · MDR 2017/745 transition in progress · ISO 13485:2016
Doping status
Play Sure Doping Free certified
Sterility
Sterile, single-use only
ISO Standard
ISO 13485:2016
Mechanism of Action

How Recross works in the joint

In osteoarthritic joints, endogenous HA concentration falls and the average molecular weight decreases, reducing synovial fluid viscosity. The result is impaired joint lubrication, increased cartilage stress under load, and progressive pain. Recross restores the viscoelastic properties of the synovial fluid through direct supplementation with exogenous sodium hyaluronate.

01
LubricationHA molecules form a viscous layer between articular surfaces, reducing friction and protecting cartilage from mechanical wear during joint movement.
02
Shock absorptionThe elastic component of HA solution absorbs mechanical impulses during loading, distributing stress more evenly across the joint surface.
03
Biological responseEvidence suggests HA supplementation stimulates endogenous HA synthesis and has anti-inflammatory effects that extend the duration of pain relief beyond the HA half-life.
HA Biomaterial Science
FEMUR FIBULA TIBIA MENISCUS CARTILAGE SYNOVIAL FLUID + RECROSS HA Coronal section, left knee. Schematic, not to scale.
Clinical Evidence

Published outcomes: Recross

For healthcare professionals. Always refer to the current instructions for use (IFU) before clinical use.

≥ 6 mo
Long-lasting pain relief from a single injection

The moderately cross-linked fraction degrades more slowly than linear hyaluronate, giving Recross prolonged cohesive residence in the joint. The effect lasts at least six months after the first injection.

Data on file · VSY Biotechnology GmbH
Safety
Well-tolerated in intra-articular use

Intra-articular viscosupplementation with Recross is a safe, well-tolerated procedure for patients with osteoarthritis who have not responded sufficiently to prior pharmacologic treatment. Report suspected side effects to the VSY Biotechnology Quality team at complaint@vsybiotechnology.com.

Data on file · VSY Biotechnology GmbH
First
Linear and moderately cross-linked hyaluronate in one

Recross is powered by VSY's proprietary HXL Hybrid XLink Technology, the first linear structured and simultaneously moderately cross-linked sodium hyaluronate, combining dispersive lubrication with cohesive shock absorption.

HXL Hybrid XLink Technology · VSY Biotechnology
View All Orthopedics Evidence